Support
News
Bionote Expands Into Veterinary Clinical Chemistry Market

DISCLAIMER: This news article is a direct translation of the original Korean article from Korea Business TV. BioNote Inc. does not claim any right to the article or claim any ownership.

The translation was completed by BioNote Inc. only for the convenience of non-Korean speaking customers and BioNote Inc. does not seek to redistribute nor acquire profit from the translation.

​​Bionote, an in vitro diagnostic product manufacturer, announced on the 23rd that they will be expanding into the clinical chemisry market, which is expected to grow to 1.25 billion USD by 2026.

Bionote also announced that they are in the process of applying for approval of domestic and international sale of their clinical chemistry analyzer 'Vcheck C' and that they will start the approval process by January.

This new product is capable of testing up to 4 samples at once, taking only 10 minutes on average, for quantitative detection of proteins, enzymes, amylase, etc. in the patient's blood samples, in order to give the veterinarian a general idea of the health of the patient in question, without sending the samples to a lab to get tested. everything can be performed on-site using this POC Clinical Chemistry Analyzer.

The Clinical Chemistry market is currently valued at 768.6 million USD, and is expected to expand up to 1.25 billion USD by 2026.

Bionote's CEO, DVM Byeong-Ki Cho, stated that "Bionote will provide a total diagnostic solution in the veterinary field through our Rapid, ELISA, Fluorescent immunoassay and POC Molecular Diagnostic devices as well as our new Clinical Chemistry analyzer, further improving our position as one of the global leaders in the veterinary field"

LIST